STOCK TITAN
  1. Home
  2. Sec-filings
  3. LKFT
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront Biotherapeutics (LKFT) repurchases 108,645 shares at €26.67

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics reported that, under its share repurchase program announced on 9 June 2026, it bought back 108,645 ordinary shares between 6 and 10 July 2026. The shares were acquired on several European trading venues at an overall average price of €26.67, for total consideration of €2,897,722.65, within a daily price range of €26.14 to €27.00.

After these transactions, Lakefront holds 412,401 of its own ordinary shares. The company, a biotechnology business focused on immunology and inflammation, highlights its clinical‑stage portfolio anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases, and refers to forward‑looking statements regarding plans to repurchase ordinary shares, which are subject to stated risks and uncertainties.

Positive

  • None.

Negative

  • None.

Filing Explained

As a Form 6-K interim report, the filing incorporates its repurchase disclosure, including Exhibit 99.1, by reference into Lakefront’s listed Form S-8 registration statements, linking this report’s contents to those registrations.

Shares repurchased 108,645 shares Repurchased between 06 and 10 July 2026 under the share buyback program announced 9 June 2026.
Average repurchase price €26.67 per share Overall average price paid for repurchased shares between 06 and 10 July 2026.
Total buyback consideration €2,897,722.65 Aggregate amount paid for 108,645 shares repurchased between 06 and 10 July 2026.
Price range during buyback €26.14–€27.00 Lowest and highest prices paid per share in the July 2026 repurchases.
Treasury shares held 412,401 shares Own ordinary shares held as of market close on 10 July 2026.
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
ordinary shares financial
"As of market close on 10 July 2026, Lakefront holds 412,401 of its own ordinary shares"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
BCMAxCD3 T‑cell engager medical
"anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What share repurchase did Lakefront Biotherapeutics (LKFT) report in July 2026?
Lakefront Biotherapeutics reported buying back 108,645 ordinary shares between 6 and 10 July 2026. The purchases were made on multiple European trading venues as part of a repurchase program announced on 9 June 2026, reflecting active capital management during the period.

At what prices did Lakefront Biotherapeutics (LKFT) repurchase its shares?
The company paid an overall average price of €26.67 per share for the repurchased stock. During the 6–10 July 2026 window, individual trades occurred within a price range of €26.14 to €27.00 across several European trading venues.

How much cash did Lakefront Biotherapeutics (LKFT) deploy on the July 2026 buyback?
Lakefront deployed €2,897,722.65 to repurchase 108,645 ordinary shares during 6–10 July 2026. This figure reflects the aggregate consideration paid across all venues under the authorized repurchase program announced on 9 June 2026.

How many treasury shares does Lakefront Biotherapeutics (LKFT) now hold?
As of market close on 10 July 2026, Lakefront Biotherapeutics holds 412,401 of its own ordinary shares. This total includes the 108,645 shares repurchased between 6 and 10 July 2026 under the ongoing share repurchase program.

What is the business focus of Lakefront Biotherapeutics (LKFT)?
Lakefront Biotherapeutics is a biotechnology company focused on immunology and inflammation. Its clinical‑stage portfolio is anchored by gamgertamig, described as a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases, supported by a strong capital position and deal‑making expertise.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On July 14, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated July 14, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: July 15, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; 14 July 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 108,645 Lakefront shares between 06 July 2026 and 10 July 2026, as follows:

Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€)
06/07/2026 XAMS 20,236 26.54 536,964.28 26.20 26.90
06/07/2026 CEUX 2,499 26.69 66,710.06 26.32 26.90
06/07/2026 TQEX 355 26.72 9,486.20 26.52 26.90
06/07/2026 AQEU 319 26.58 8,477.65 26.52 26.88
07/07/2026 XAMS 16,553 26.65 441,104.34 26.40 26.86
07/07/2026 CEUX 1,578 26.55 41,894.01 26.44 26.76
07/07/2026 TQEX 821 26.64 21,872.92 26.60 26.70
07/07/2026 AQEU 49 26.60 1,303.40 26.60 26.60
08/07/2026 XAMS 17,502 26.84 469,793.93 26.66 27.00
08/07/2026 CEUX 4,339 26.89 116,674.84 26.74 26.96
08/07/2026 TQEX 1,157 26.87 31,086.62 26.76 26.94
08/07/2026 AQEU 416 26.86 11,172.18 26.80 26.94
09/07/2026 XAMS 16,919 26.77 452,892.87 26.56 26.90
09/07/2026 CEUX 2,717 26.79 72,781.09 26.70 26.96
09/07/2026 TQEX 23 26.76 615.48 26.76 26.76
09/07/2026 AQEU 400 26.77 10,707.04 26.76 26.78
10/07/2026 XAMS 19,764 26.52 524,208.48 26.14 26.90
10/07/2026 CEUX 2,009 26.66 53,568.98 26.26 26.92
10/07/2026 TQEX 692 26.65 18,443.74 26.24 26.78
10/07/2026 AQEU 297 26.82 7,964.53 26.26 26.92
Total   108,645 26.67 2,897,722.65 26.14 27.00

As of market close on 10 July 2026, Lakefront holds 412,401 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases